Study Details

Back to Search Results

Gene Transfer Clinical Study in X-Linked Myotubular Myopathy

Recruitment complete
The study is ongoing, and participants are receiving an intervention or being examined, but potential participants are not currently being recruited or enrolled.

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT03199469

Astellas Study ID

The unique identification code given by the study sponsor.

ATX-MTM-002

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

2017-000876-27

Follow Trial

Condition

X-Linked Myotubular Myopathy

Phase

These clinical trials are usually the first time an experimental treatment is studied in a small group of people.

Phase 1

Age

N/A - 5 Years

Sex

Male

Product

N/A

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Aug 2017 - Oct 2030

Masking

None (Open Label)

Enrollment number

26

ASPIRO: A Phase 1/2/3, Randomized, Open-Label, Ascending-Dose, Delayed-Treatment Concurrent Control Clinical Study to Evaluate the Safety and Efficacy of AT132, an AAV8-Delivered Gene Therapy in X-Linked Myotubular Myopathy (XLMTM) Patients

Study summary

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for Gene Transfer Clinical Study in X-Linked Myotubular Myopathy? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Ann & Robert H Lurie Children's Hospital of Chicago

Chicago, United States, 60611

UCLA Medical Center

Los Angeles, United States, 90095

Hopital Armad Trousseau

Paris, France, 75012

Hospital for Sick Children

Toronto, Canada, M5G0A4

National Institute of Neurological Disorders and Stroke/NIH Porter

Bethesda, United States, 208892

Kinderklinik und Kinderpoliklinik im Dr. Von Haunerschen Kinderspital Klinikum der Universitat Munchen

München, Germany, 80337

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo